Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Results (all patients)

From: Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

    SBRT CF-EBRT p-value
   Through year    
PSA Measurements #     
  Mean (range) 1 3.9 (2 – 6) 4.1 (3 – 11)  
   2 5.8 (4 – 9) 5.6 (3 – 15)  
   3 7.6 (5 – 11) 7.3 (3 – 21)  
Nadir PSA (ng/mL)     
  Median (range) 1 0.70 (0 – 2.5) 1.00 (0 – 8.5)  
   2 0.40 (0 – 1.4) 0.72 (0 – 2.7) p = 0.0005*
   3 0.24 (0.1 – 1.4) 0.60 (0 – 2.2) p = 0.002*
Time to Nadir PSA (mos.)     
  Median (range) 1 12.0 (2.7 – 15.0) 11.5 (1.2 – 15.0)  
   2 21.0 (2.7 – 26.9) 18.0 (1.2 – 26.9)  
   3 32.3 (2.7 – 41.6) 28.6 (1.0 – 41.1) p = 0.004^
Rate of PSA change: ng/mL/month    
  Median slope (range) 1 -0.09 (-0.88, 0.04) -0.09 (-0.60, 0.06)  
   2 -0.06 (-0.38, 0.01) -0.04 (-0.65, 0.05) p = 0.04*
   3 -0.05 (-0.19, 0.00) -0.02 (-0.38, 0.04) p = 0.006*
  1. SBRT: Stereotactic Body Radiotherapy.
  2. CF-EBRT: Conventionally fractionated external beam radiotherapy.
  3. p: Statistical significance.
  4. # The t test was performed to compare the mean number of PSA measurements between the two groups for each interval with means and ranges presented to summarize the results.
  5. ^ The log rank test was used due to compare the time to nadir PSA distributions between the two groups for each interval with medians and ranges presented to summarize the results.
  6. * The Mann–Whitney test was performed to compare the PSA nadir and slope distributions between the two groups with medians and ranges presented to summarize the results.